Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Paladin Labs licenses Savene rights from SpePharm

Executive Summary

Immediately after it received rights to the drug from TopoTarget, SpePharm Holding BV is licensing fellow spec pharma Paladin Labs exclusive rights to develop and sell Savene (dexrazoxane) in South Africa and Israel, a move that helps the Paladin greatly expand its international reach.
Deal Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity

Related Companies

Advertisement
UsernamePublicRestriction

Register